Journal
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
Volume 20, Issue 2, Pages 67-68Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41575-022-00717-4
Keywords
-
Categories
Ask authors/readers for more resources
The year 2022 witnessed significant progress in both the NAFLD and obesity fields. Advancements in pharmacological treatment offer the potential for replacing bariatric surgery, while the application of artificial intelligence helps in evaluating histological effects of new drugs. Moreover, personalized screening for hepatocellular carcinoma in patients with NAFLD has also seen improvement.
2022 was a proficuous year in both the nonalcoholic fatty liver disease (NAFLD) and obesity fields. Pharmacological treatment for obesity and NAFLD is moving forward, with the possibility of replacing bariatric surgery, artificial intelligence might help us access the histological effects of new drugs, and there were advances in personalized hepatocellular carcinoma screening in patients with NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
